News Releases

SAN FRANCISCO --(BUSINESS WIRE)--Sep. 7, 2021-- Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will

Phase 2 Program in Pediatric Classic Congenital Adrenal Hyperplasia (CAH) on Track to Initiate in 2021 with Data Expected by 1H 2023 Phase 3 Registrational Program in Pediatric Classic CAH Expected to Initiate in 2023 R&D Day Webcast Featuring Spruce Management, KOL Panel Discussion and Q&A Begins

Presentations from Spruce leadership team & KOL panel discussion featuring Richard Auchus, MD, PhD and Paul Thornton, MD San Francisco, Calif. – August 11, 2021 – Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel

Clearance of IND for Treatment of Polycystic Ovary Syndrome New Patent Broadens Tildacerfont Intellectual Property Estate in Congenital Adrenal Hyperplasia Publication of Tildacerfont Phase 2 Data in the Journal of Clinical Endocrinology and Metabolism SAN FRANCISCO --(BUSINESS WIRE)--Aug.

Dr. Ways’ Expertise in Late-Stage Clinical Development in Therapeutics Areas of High Unmet Medical Meet Supports Spruce’s Goal to Expand Portfolio of Indications for Tildacerfont SAN FRANCISCO --(BUSINESS WIRE)--Jun. 24, 2021-- Spruce Biosciences, Inc.

Tildacerfont was Evaluated in Two Phase 2 Open-Label Studies in Adults with Classic Congenital Adrenal Hyperplasia (CAH) Data Demonstrated Normalization or Trend to Normalization in Key Hormone Biomarkers Tildacerfont is First CRF1 Receptor Antagonist Studied Beyond 2 Weeks in CAH SAN FRANCISCO

Richard Auchus , MD, PhD, Presents Phase 2 Data of Tildacerfont in Adult Classic CAH Tildacerfont Demonstrates Normalization of Elevated Hormone Levels Without Increases to Daily Steroid Doses CAHmelia Clinical Program in Adult Classic CAH Underway to Assess Hormone and Steroid Reduction SAN

SAN FRANCISCO --(BUSINESS WIRE)--May 13, 2021-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Richard King , Chief

Presentation of Phase 2 Data of Tildacerfont at 23 rd Annual European Congress of Endocrinology   Cash and Cash Equivalents of $148.6 million SAN FRANCISCO --(BUSINESS WIRE)--May 12, 2021-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and

Late-Stage CAHmelia Program in Adult Classic CAH Advancing with Majority of Study Sites Active CAHmelia Program Enhanced Following Discussions with FDA - Primary Data Expected in 2022 Amended Debt Facility with SVB Provides Access Up to Additional $25 Million in Non-Dilutive Financing New Drug